Symbols / MDXH Stock $0.57 -5.68% MDxHealth SA

Healthcare • Diagnostics & Research • Belgium • NCM
MDXH (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Mr. Michael K. McGarrity
Exch · Country NCM · Belgium
Market Cap 29.07M
Enterprise Value 94.03M
Income -33.18M
Sales 110.97M
FCF (ttm) -15.48M
Book/sh -0.39
Cash/sh 0.83
Employees 364
Insider 10d —
IPO Nov 04, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.35
PEG —
P/S 0.26
P/B -1.46
P/C —
EV/EBITDA -8.77
EV/Sales 0.85
Quick Ratio 1.38
Current Ratio 1.63
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.65
EPS next Y -0.13
EPS Growth —
Revenue Growth 12.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-13
Earnings (prior) 2026-05-13
ROA -6.38%
ROE —
ROIC —
Gross Margin 63.75%
Oper. Margin -26.67%
Profit Margin -29.90%
Shs Outstand 51.36M
Shs Float 36.24M
Insider Own 11.13%
Instit Own 48.65%
Short Float 2.35%
Short Ratio 1.07
Short Interest 910.29K
52W High 5.33
vs 52W High -89.38%
52W Low 0.51
vs 52W Low 10.96%
Beta -506,982.72
Impl. Vol. —
Rel Volume 1.77
Avg Volume 570.35K
Volume 1.01M
Target (mean) $3.90
Tgt Median $4.00
Tgt Low $1.50
Tgt High $6.00
# Analysts 5
Recom None
Prev Close $0.60
Price $0.57
Change -5.68%
About

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$3.90
Mean price target
2. Current target
$0.57
Latest analyst target
3. DCF / Fair value
$-5.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.57
Low
$1.50
High
$6.00
Mean
$3.90

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-14 main Lake Street Buy → Buy $5
2026-05-14 main TD Cowen Buy → Buy $2
2026-05-14 main BTIG Buy → Buy $4
2025-12-23 reit BTIG Buy → Buy $7
2025-11-13 main TD Cowen Buy → Buy $7
2025-11-13 main Lake Street Buy → Buy $9
2025-11-13 main BTIG Buy → Buy $7
2024-11-07 main Piper Sandler Overweight → Overweight $6
2024-10-31 init Lake Street — → Buy $7
2024-03-07 main Piper Sandler Overweight → Overweight $7
2024-03-07 main BTIG Buy → Buy $8
News
RSS: Latest MDXH news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
107.88
+19.80%
90.05
+28.29%
70.19
+89.43%
37.05
Operating Revenue
107.88
+19.80%
90.05
+28.29%
70.19
+125.33%
31.15
Cost Of Revenue
38.24
+9.55%
34.91
+32.91%
26.26
+47.26%
17.84
Reconciled Cost Of Revenue
36.97
+8.22%
34.16
+33.83%
25.52
+45.20%
17.58
Gross Profit
69.63
+26.28%
55.14
+25.52%
43.93
+128.57%
19.22
Operating Expense
85.00
+7.37%
79.17
+12.03%
70.67
+22.62%
57.63
Research And Development
10.35
-1.91%
10.55
+65.50%
6.38
+15.99%
5.50
Selling General And Administration
66.75
+8.72%
61.40
+5.31%
58.30
+22.66%
47.53
Selling And Marketing Expense
7.77
+20.66%
6.44
-12.53%
7.37
+59.24%
4.62
General And Administrative Expense
58.98
+7.32%
54.95
+7.89%
50.94
+18.72%
42.90
Salaries And Wages
46.50
+2.16%
45.52
+19.36%
38.14
+35.88%
28.07
Other Gand A
12.47
+32.22%
9.44
-26.28%
12.80
-13.74%
14.84
Other Operating Expenses
-0.03
+56.34%
-0.07
+44.09%
-0.13
-188.64%
-0.04
Total Expenses
123.25
+8.04%
114.08
+17.69%
96.93
+28.44%
75.47
Operating Income
-15.37
+36.03%
-24.03
+10.14%
-26.74
+30.39%
-38.41
Total Operating Income As Reported
-14.41
+41.72%
-24.72
+9.53%
-27.33
+27.90%
-37.90
EBITDA
-14.55
+33.91%
-22.02
+28.18%
-30.66
+16.00%
-36.50
Normalized EBITDA
-4.91
+67.76%
-15.23
+24.28%
-20.11
+39.95%
-33.49
Reconciled Depreciation
9.21
+14.54%
8.04
+17.20%
6.86
+39.72%
4.91
EBIT
-23.76
+20.95%
-30.06
+19.88%
-37.52
+9.40%
-41.41
Total Unusual Items
-9.64
-41.98%
-6.79
+35.61%
-10.55
-250.32%
-3.01
Total Unusual Items Excluding Goodwill
-9.64
-41.98%
-6.79
+35.61%
-10.55
-250.32%
-3.01
Special Income Charges
-9.67
-25.07%
-7.73
+20.62%
-9.74
-211.54%
-3.13
Other Special Charges
—
3.13
—
1.05
Impairment Of Capital Assets
0.16
—
—
—
Restructuring And Mergern Acquisition
9.51
+106.65%
4.60
-52.75%
9.74
+368.37%
2.08
Net Income
-33.52
+11.95%
-38.07
+11.67%
-43.10
+2.14%
-44.04
Pretax Income
-35.38
+6.13%
-37.69
+12.56%
-43.10
+2.15%
-44.04
Net Non Operating Interest Income Expense
-10.36
-50.86%
-6.87
-18.17%
-5.81
-122.00%
-2.62
Interest Expense Non Operating
11.62
+52.26%
7.63
+36.67%
5.58
+111.76%
2.64
Net Interest Income
-10.36
-50.86%
-6.87
-18.17%
-5.81
-122.00%
-2.62
Interest Expense
11.62
+52.26%
7.63
+36.67%
5.58
+111.76%
2.64
Interest Income Non Operating
1.50
+39.33%
1.08
-0.92%
1.09
+770.40%
0.12
Interest Income
1.50
+39.33%
1.08
-0.92%
1.09
+770.40%
0.12
Other Income Expense
-9.64
-41.98%
-6.79
+35.61%
-10.55
-250.32%
-3.01
Gain On Sale Of Security
0.03
-96.92%
0.94
+216.75%
-0.81
-794.83%
0.12
Tax Provision
-1.86
-586.13%
0.38
+38100.00%
0.00
0.00
Tax Rate For Calcs
0.00
-75.00%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
-0.51
+64.51%
-1.43
+35.61%
-2.22
0.00
Net Income Including Noncontrolling Interests
-33.52
+11.95%
-38.07
+11.67%
-43.10
+2.14%
-44.04
Net Income From Continuing Operation Net Minority Interest
-33.52
+11.95%
-38.07
+11.67%
-43.10
+2.14%
-44.04
Net Income From Continuing And Discontinued Operation
-33.52
+11.95%
-38.07
+11.67%
-43.10
+2.14%
-44.04
Net Income Continuous Operations
-33.52
+11.95%
-38.07
+11.67%
-43.10
+2.14%
-44.04
Normalized Income
-24.38
+25.44%
-32.70
+5.94%
-34.77
+15.27%
-41.03
Net Income Common Stockholders
-33.52
+11.95%
-38.07
+11.67%
-43.10
+2.14%
-44.04
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
-0.67
+42.24%
-1.16
+30.12%
-1.66
+40.71%
-2.80
Basic EPS
-0.67
+42.24%
-1.16
+30.12%
-1.66
+40.71%
-2.80
Basic Average Shares
50.03
+1.07%
49.50
+90.64%
25.96
+65.06%
15.73
Diluted Average Shares
50.03
+1.07%
49.50
+90.64%
25.96
+65.06%
15.73
Diluted NI Availto Com Stockholders
-33.52
+11.95%
-38.07
+11.67%
-43.10
+2.14%
-44.04
Amortization
5.19
+5.85%
4.91
+9.15%
4.49
+41.81%
3.17
Amortization Of Intangibles Income Statement
5.19
+5.85%
4.91
+9.15%
4.49
+41.81%
3.17
Depreciation Amortization Depletion Income Statement
7.93
+8.81%
7.29
+19.15%
6.12
+31.51%
4.65
Depreciation And Amortization In Income Statement
7.93
+8.81%
7.29
+19.15%
6.12
+31.51%
4.65
Depreciation Income Statement
2.74
+14.88%
2.39
+46.83%
1.62
+9.50%
1.48
Total Other Finance Cost
0.25
-22.08%
0.32
-75.95%
1.32
+1131.78%
0.11
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
147.95
-5.96%
157.33
+21.84%
129.13
+8.39%
119.14
Current Assets
53.41
-20.16%
66.89
+75.30%
38.16
+30.92%
29.15
Cash Cash Equivalents And Short Term Investments
29.03
-37.96%
46.80
+109.11%
22.38
+44.36%
15.50
Cash And Cash Equivalents
29.03
-37.96%
46.80
+109.11%
22.38
+44.36%
15.50
Receivables
14.73
+1.35%
14.53
+28.93%
11.27
+18.54%
9.51
Accounts Receivable
14.68
+1.63%
14.44
+30.23%
11.09
+18.50%
9.36
Other Receivables
—
—
—
0.05
Taxes Receivable
0.05
-42.39%
0.09
-49.73%
0.18
+88.66%
0.10
Inventory
6.74
+74.23%
3.87
+39.22%
2.78
+19.42%
2.33
Raw Materials
6.90
+78.26%
3.87
+39.22%
2.78
+19.42%
2.33
Prepaid Assets
1.97
+16.04%
1.70
+0.06%
1.70
-6.41%
1.81
Assets Held For Sale Current
0.94
0.00
—
—
Other Current Assets
—
—
0.04
—
Total Non Current Assets
94.54
+4.54%
90.43
-0.59%
90.97
+1.09%
89.99
Net PPE
14.68
+13.07%
12.98
+30.50%
9.95
+25.99%
7.89
Gross PPE
27.60
+18.72%
23.25
+2.06%
22.78
+22.78%
18.55
Accumulated Depreciation
-12.93
-25.86%
-10.27
+19.99%
-12.83
-20.41%
-10.66
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
12.28
+31.99%
9.31
+27.65%
7.29
+11.06%
6.57
Machinery Furniture Equipment
1.53
-11.42%
1.73
-9.50%
1.91
+16.79%
1.63
Other Properties
10.80
+12.61%
9.59
-11.09%
10.79
+29.98%
8.30
Leases
2.99
+13.82%
2.63
-6.08%
2.80
+35.91%
2.06
Goodwill And Other Intangible Assets
78.37
+2.42%
76.52
-4.67%
80.26
-2.23%
82.09
Goodwill
38.95
+8.41%
35.93
+0.00%
35.93
+0.00%
35.93
Other Intangible Assets
39.42
-2.88%
40.59
-8.45%
44.34
-3.96%
46.17
Investments And Advances
1.50
+59.83%
0.94
+22.67%
0.76
0.00
Other Non Current Assets
—
—
-0.00
—
Total Liabilities Net Minority Interest
160.05
+12.32%
142.49
+16.87%
121.92
+11.02%
109.82
Current Liabilities
49.53
+16.11%
42.66
+118.53%
19.52
+6.81%
18.28
Payables And Accrued Expenses
17.07
+17.18%
14.57
+0.43%
14.51
+2.41%
14.16
Payables
10.33
+29.11%
8.00
-9.19%
8.81
-13.43%
10.18
Accounts Payable
10.33
+29.11%
8.00
-9.19%
8.81
-13.43%
10.18
Current Accrued Expenses
6.74
+2.65%
6.57
+15.33%
5.69
+42.89%
3.98
Current Debt And Capital Lease Obligation
1.90
+12.71%
1.68
-20.68%
2.12
+18.74%
1.79
Current Debt
—
0.32
-49.61%
0.64
+4.38%
0.62
Other Current Borrowings
—
0.32
-49.61%
0.64
+4.38%
0.62
Current Capital Lease Obligation
1.90
+39.56%
1.36
-8.11%
1.48
+26.28%
1.17
Other Current Liabilities
30.57
+15.73%
26.41
+812.30%
2.90
+24.41%
2.33
Total Non Current Liabilities Net Minority Interest
110.51
+10.71%
99.83
-2.52%
102.40
+11.86%
91.54
Long Term Debt And Capital Lease Obligation
84.71
+45.09%
58.38
+49.15%
39.14
+2.99%
38.01
Long Term Debt
76.20
+49.50%
50.97
+43.31%
35.56
+1.86%
34.91
Long Term Capital Lease Obligation
8.51
+14.78%
7.41
+107.18%
3.58
+15.76%
3.09
Other Non Current Liabilities
25.81
-37.73%
41.45
-34.48%
63.26
+18.16%
53.54
Stockholders Equity
-12.09
-181.49%
14.84
+105.90%
7.21
-22.62%
9.31
Common Stock Equity
-12.09
-181.49%
14.84
+105.90%
7.21
-22.62%
9.31
Capital Stock
219.21
+2.11%
214.67
+23.42%
173.93
+30.33%
133.45
Common Stock
219.21
+2.11%
214.67
+23.42%
173.93
+30.33%
133.45
Share Issued
51.36
+3.77%
49.50
+81.39%
27.29
+67.53%
16.29
Ordinary Shares Number
51.36
+3.77%
49.50
+81.39%
27.29
+67.53%
16.29
Additional Paid In Capital
153.18
+0.00%
153.18
+0.00%
153.18
+0.00%
153.18
Retained Earnings
-403.03
-9.07%
-369.51
-11.49%
-331.45
-14.95%
-288.35
Gains Losses Not Affecting Retained Earnings
-0.78
-26.99%
-0.61
-3.71%
-0.59
-33.56%
-0.44
Total Equity Gross Minority Interest
-12.09
-181.49%
14.84
+105.90%
7.21
-22.62%
9.31
Total Capitalization
64.10
-2.59%
65.81
+53.86%
42.77
-3.29%
44.23
Working Capital
3.88
-84.01%
24.23
+30.01%
18.64
+71.45%
10.87
Total Debt
86.60
+44.19%
60.06
+45.56%
41.27
+3.70%
39.79
Net Debt
47.16
+949.74%
4.49
-67.51%
13.83
-30.96%
20.03
Capital Lease Obligations
10.41
+18.63%
8.77
+73.45%
5.06
+18.65%
4.26
Net Tangible Assets
-90.47
-46.68%
-61.68
+15.57%
-73.06
-0.38%
-72.78
Tangible Book Value
-90.47
-46.68%
-61.68
+15.57%
-73.06
-0.38%
-72.78
Available For Sale Securities
1.50
+59.83%
0.94
+22.67%
0.76
—
Foreign Currency Translation Adjustments
-0.78
-26.99%
-0.61
-3.71%
-0.59
-33.56%
-0.44
Inventories Adjustments Allowances
-0.68
0.00
—
—
Investmentin Financial Assets
1.50
+59.83%
0.94
+22.67%
0.76
0.00
Other Equity Interest
19.34
+12.91%
17.12
+41.07%
12.14
+5.80%
11.47
Other Inventories
0.53
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-2.19
+88.19%
-18.53
+13.80%
-21.50
+36.99%
-34.12
Cash Flow From Continuing Operating Activities
-2.19
+88.19%
-18.53
+13.80%
-21.50
+36.99%
-34.12
Net Income From Continuing Operations
-14.41
+41.72%
-24.72
+9.53%
-27.33
+27.90%
-37.90
Depreciation Amortization Depletion
9.21
+14.54%
8.04
+17.20%
6.86
+39.72%
4.91
Depreciation
4.02
+28.14%
3.13
+32.52%
2.37
+35.92%
1.74
Amortization Cash Flow
5.19
+5.85%
4.91
+9.15%
4.49
+41.81%
3.17
Depreciation And Amortization
9.21
+14.54%
8.04
+17.20%
6.86
+39.72%
4.91
Amortization Of Intangibles
5.19
+5.85%
4.91
+9.15%
4.49
+41.81%
3.17
Other Non Cash Items
-0.82
-387.41%
0.29
-32.07%
0.42
+189.01%
-0.47
Stock Based Compensation
2.21
+28.17%
1.73
+159.40%
0.67
-23.30%
0.87
Provisionand Write Offof Assets
0.68
0.00
0.00
—
Asset Impairment Charge
—
0.00
0.00
-100.00%
0.04
Change In Working Capital
0.94
+124.34%
-3.86
-82.41%
-2.12
-35.14%
-1.56
Change In Receivables
2.32
+171.92%
-3.23
-91.68%
-1.68
+67.14%
-5.12
Change In Inventory
-1.93
-77.16%
-1.09
-141.15%
-0.45
-8.65%
-0.42
Change In Payables And Accrued Expense
0.55
+20.09%
0.46
+2190.00%
0.02
-99.50%
3.97
Change In Payable
0.55
+20.09%
0.46
+2190.00%
0.02
-99.50%
3.97
Investing Cash Flow
-18.56
-1034.35%
-1.64
+58.38%
-3.93
+86.46%
-29.04
Cash Flow From Continuing Investing Activities
-18.56
-1034.35%
-1.64
+58.38%
-3.93
+86.46%
-29.04
Net PPE Purchase And Sale
-1.16
+2.61%
-1.19
+56.75%
-2.75
+1.51%
-2.79
Purchase Of PPE
-1.16
+2.61%
-1.19
+56.75%
-2.75
+1.51%
-2.79
Capital Expenditure
-1.16
+46.41%
-2.16
+56.98%
-5.02
-20.56%
-4.16
Net Business Purchase And Sale
0.76
0.00
0.00
+100.00%
-25.00
Purchase Of Business
—
0.00
0.00
+100.00%
-25.00
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.97
+57.26%
-2.27
-65.36%
-1.37
Purchase Of Intangibles
0.00
+100.00%
-0.97
+57.26%
-2.27
-65.36%
-1.37
Net Other Investing Changes
-19.66
-3441.98%
-0.56
—
—
Financing Cash Flow
2.96
-93.35%
44.60
+38.16%
32.28
+55.82%
20.72
Cash Flow From Continuing Financing Activities
2.96
-93.35%
44.60
+38.16%
32.28
+55.82%
20.72
Net Issuance Payments Of Debt
21.60
+86.43%
11.59
+454.48%
-3.27
-114.77%
22.13
Issuance Of Debt
24.25
-54.25%
53.01
0.00
-100.00%
34.29
Repayment Of Debt
-2.65
+93.61%
-41.42
-1167.15%
-3.27
+73.12%
-12.16
Long Term Debt Issuance
24.25
-54.25%
53.01
0.00
-100.00%
34.29
Long Term Debt Payments
-2.65
+93.61%
-41.42
-1167.15%
-3.27
+73.12%
-12.16
Net Long Term Debt Issuance
21.60
+86.43%
11.59
+454.48%
-3.27
-114.77%
22.13
Net Common Stock Issuance
0.00
-100.00%
40.74
+2.88%
39.60
0.00
Cash Dividends Paid
0.00
0.00
0.00
0.00
Net Other Financing Charges
-8.91
-767.48%
-1.03
-133.41%
-0.44
-452.00%
0.12
Changes In Cash
-17.78
-172.78%
24.43
+256.57%
6.85
+116.15%
-42.44
Effect Of Exchange Rate Changes
0.02
+214.29%
-0.01
-156.00%
0.03
+104.50%
-0.56
Beginning Cash Position
46.80
+109.11%
22.38
+44.36%
15.50
-73.50%
58.50
End Cash Position
29.03
-37.96%
46.80
+109.11%
22.38
+44.36%
15.50
Free Cash Flow
-3.35
+83.83%
-20.69
+21.98%
-26.52
+30.73%
-38.28
Common Stock Issuance
0.00
-100.00%
40.74
+2.88%
39.60
0.00
Interest Paid CFF
-9.73
-45.18%
-6.70
-85.65%
-3.61
-155.67%
-1.41
Interest Received CFI
1.50
+39.33%
1.08
-0.92%
1.09
+770.40%
0.12
Issuance Of Capital Stock
0.00
-100.00%
40.74
+2.88%
39.60
0.00
Sale Of Business
0.76
0.00
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category